Honokiol inhibits bladder cancer cell invasion through repressing SRC‑3 expression and epithelial‑mesenchymal transition

Shen,Lan; Zhang,Fang; Huang,Ruimin; Yan,Jun; Shen,Bing

doi:10.3892/ol.2017.6665

Honokiol inhibits bladder cancer cell invasion through repressing SRC‑3 expression and epithelial‑mesenchymal transition

Authors:
- Lan Shen
- Fang Zhang
- Ruimin Huang
- Jun Yan
- Bing Shen
View Affiliations

Affiliations: State Key Laboratory of Pharmaceutical Biotechnology and MOE Key Laboratory of Model Animals for Disease Study, Model Animal Research Center of Nanjing University, Nanjing, Jiangsu 210061, P.R. China, Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, P.R. China, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China
Published online on: July 25, 2017 https://doi.org/10.3892/ol.2017.6665
Pages: 4294-4300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urinary bladder cancer (UBC) is one of the most common urological cancer types. Muscle invasive bladder cancer possesses high propensity for metastasis with poor prognosis. Honokiol is a lignan isolated from Magnolia officinalis with high bioavailability and potent anticancer effects. The results of the present study demonstrated that honokiol significantly inhibited UBC cell migration and invasion in a dose‑dependent manner compared with the vehicle‑treated control group. In addition, honokiol treatment suppressed epithelial‑mesenchymal transition by induction of E‑cadherin and repression of N‑cadherin. Honokiol was capable of significantly downregulating the expression of cell invasion‑associated genes, steroid receptor coactivator‑3 (SRC‑3), matrix metalloproteinase (MMP)‑2 and Twist1. Notably, the inhibition of UBC cell invasion by honokiol was reversed by reintroduction of oncoprotein SRC‑3 expression, with the restoration of MMP‑2 and Twist1, and reduction of E‑cadherin expression. Furthermore, the results of the luciferase assay confirmed that SRC‑3 could regulate Twist1 promoter activity. Taken together, the results of the present study suggest that honokiol is a promising agent against UBC cell invasion via downregulation of SRC‑3 and its target genes.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zheng R, Zeng H, Zhang S, Chen T and Chen W: National estimates of cancer prevalence in China, 2011. Cancer Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
3	Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 277:965–968. 1997. View Article : Google Scholar : PubMed/NCBI
4	Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY and Tsai MJ: SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65:7976–7983. 2005. View Article : Google Scholar : PubMed/NCBI
5	Yan J, Tsai SY and Tsai MJ: SRC-3/AIB1: Transcriptional coactivator in oncogenesis. Acta Pharmacol Sin. 27:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW and Xu J: Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid Biochem Mol Biol. 83:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
7	Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, et al: Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 70:6477–6485. 2010. View Article : Google Scholar : PubMed/NCBI
8	Long W, Foulds CE, Qin J, Liu J, Ding C, Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, et al: ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 122:1869–1880. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhao W, Chang C, Cui Y, Zhao X, Yang J, Shen L, Zhou J, Hou Z, Zhang Z, Ye C, et al: Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α. J Biol Chem. 289:11219–11229. 2014. View Article : Google Scholar : PubMed/NCBI
10	Luo JH, Xie D, Liu MZ, Chen W, Liu YD, Wu GQ, Kung HF, Zeng YX and Guan XY: Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer. 122:2554–2561. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY and Tsai MJ: Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68:5460–5468. 2008. View Article : Google Scholar : PubMed/NCBI
12	Louie MC, Zou JX, Rabinovich A and Chen HW: ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol. 24:5157–5171. 2004. View Article : Google Scholar : PubMed/NCBI
13	Tong ZT, Wei JH, Zhang JX, Liang CZ, Liao B, Lu J, Fan S, Chen ZH, Zhang F, Ma HH, et al: AIB1 predicts bladder cancer outcome and promotes bladder cancer cell proliferation through AKT and E2F1. Br J Cancer. 108:1470–1479. 2013. View Article : Google Scholar : PubMed/NCBI
14	Watanabe K, Watanabe HY, Goto Y, Yamamoto N and Yoshizaki M: Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol. Jpn J Pharmacol. 25:605–607. 1975. View Article : Google Scholar : PubMed/NCBI
15	Arora S, Singh S, Piazza GA, Contreras CM, Panyam J and Singh AP: Honokiol: A novel natural agent for cancer prevention and therapy. Curr Mol Med. 12:1244–1252. 2012. View Article : Google Scholar : PubMed/NCBI
16	Esumi T, Makado G, Zhai H, Shimizu Y, Mitsumoto Y and Fukuyama Y: Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg Med Chem Lett. 14:2621–2625. 2004. View Article : Google Scholar : PubMed/NCBI
17	Zhang Q, Zhao W, Ye C, Zhuang J, Chang C, Li Y, Huang X, Shen L, Li Y, Cui Y, et al: Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget. 6:37335–37348. 2015. View Article : Google Scholar : PubMed/NCBI
18	Cheng S, Castillo V, Eliaz I and Sliva D: Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling. Int J Oncol. 46:2293–2298. 2015. View Article : Google Scholar : PubMed/NCBI
19	Jeong JJ, Lee JH, Chang KC and Kim HJ: Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int J Oncol. 41:1358–1364. 2012. View Article : Google Scholar : PubMed/NCBI
20	Khan MA, Tania M, Wei C, Mei Z, Fu S, Cheng J, Xu J and Fu J: Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget. 6:19580–19591. 2015. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) methods. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Gheldof A and Berx G: Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
23	Tania M, Khan MA and Fu J: Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI
24	McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
25	Khan MA, Chen HC, Zhang D and Fu J: Twist: A molecular target in cancer therapeutics. Tumour Biol. 34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
26	Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S and Szarvas T: The prognostic value of cadherin switch in bladder cancer. Oncol Rep. 23:1125–1132. 2010.PubMed/NCBI
27	Guo S, Xu J, Xue R, Liu Y and Yu H: Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol. 19:319–324. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wang M, Zhao F, Li S, Chang AK, Jia Z, Chen Y, Xu F, Pan H and Wu H: AIB1 cooperates with ERα to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation. PLoS One. 8:e655562013. View Article : Google Scholar : PubMed/NCBI
29	Qin L, Liu Z, Chen H and Xu J: The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res. 69:3819–3827. 2009. View Article : Google Scholar : PubMed/NCBI
30	Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA and Yeh S: Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 5:7917–7935. 2014. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG and O'Malley BW: Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol. 25:2041–2053. 2011. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, et al: Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 74:1506–1517. 2014. View Article : Google Scholar : PubMed/NCBI
33	Yan F, Yu Y, Chow DC, Palzkill T, Madoux F, Hodder P, Chase P, Griffin PR, O'Malley BW and Lonard DM: Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One. 9:e952432014. View Article : Google Scholar : PubMed/NCBI
34	Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK and Sharma D: Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 8:565–580. 2014. View Article : Google Scholar : PubMed/NCBI
35	Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL and Grandis JR: Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 16:2571–2579. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL and Aggarwal BB: Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 4:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
37	Liu SH, Lee WJ, Lai DW, Wu SM, Liu CY, Tien HR, Chiu CS, Peng YC, Jan YJ, Chao TH, et al: Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition. Mol Oncol. 9:834–849. 2015. View Article : Google Scholar : PubMed/NCBI
38	Joo YN, Eun SY, Park SW, Lee JH, Chang KC and Kim HJ: Honokiol inhibits U87MG human glioblastoma cell invasion through endothelial cells by regulating membrane permeability and the epithelial-mesenchymal transition. Int J Oncol. 44:187–194. 2014. View Article : Google Scholar : PubMed/NCBI